Tirzepatide

Evidence Anchor

BioHarmony 6.1/10

Tirzepatide delivers clinically meaningful weight loss and glycemic improvement for adults with obesity or type 2 diabetes, but the benefits depend on ongoing weekly injections. The evidence shows average reductions of 15-20% body weight and HbA1c drops of 1-1.5% in trial populations, with the strongest signals in people whose BMI exceeds 35 kg/m2 or who have prediabetes [Jastreboff 2025](https://pubmed.ncbi.nlm.nih.gov/39536238/). Systematic reviews confirm that tirzepatide outperforms placebo and most comparators across diverse cohorts, while gastrointestinal upset remains the most common adverse event [Cerchi 2025](https://www.nature.com/articles/s41366-025-01920-4). Durability wanes after discontinuation, so candidates should be prepared for a long-term treatment plan integrated with diet, resistance training, and regular metabolic monitoring. Individuals without significant metabolic dysfunction, who seek short-term cosmetic change, or who cannot tolerate chronic injection regimens are less likely to achieve a favorable risk-benefit balance. ✅ Best for: Adults with BMI >=35 where time-to-effect matters and obesity complications are progressing despite serious lifestyle effort. Type 2 diabetics with poor glycemic control despite standard care. Adults with obesity and prediabetes where diabetes prevention is a primary goal, supported by Jastreboff 2025. HFpEF with obesity under cardiology supervision, supported by Packer 2025. Adults with obesity-related OSA using tirzepatide as adjunctive chronic disease care, not as a reason to abandon PAP without retesting. People who have accepted the long-term therapy model and paired the drug with resistance training, high protein, creatine, and body-composition monitoring. ❌ Avoid if: You have a personal or family history of medullary thyroid carcinoma or MEN2; are pregnant, trying to conceive, or unwilling to plan washout; have prior pancreatitis or severe gastric motility disease without specialist oversight; use oral contraceptives without discussing non-oral backup; have type 1 diabetes or use insulin / sulfonylureas without clinician dose adjustment; are over 60 with sarcopenia or osteoporosis risk and no plan to monitor muscle and bone; want a short-term detox, reset, or cosmetic cut; or are sourcing from gray-market research peptide sellers instead of regulated prescription channels. For people with 15-30 pounds to lose and no serious metabolic disease, the lifetime-drug model usually fails the risk-benefit test.

Read the full BioHarmony report

My score and my verdict: one signal of three, never the whole answer.